Literature DB >> 24402042

Outcome characteristics of multiple-valve surgery: comparison with single-valve procedures.

Christina M Vassileva1, Shuang Li, Vinod H Thourani, Rakesh M Suri, Matthew L Williams, Richard Lee, J Scott Rankin.   

Abstract

OBJECTIVE: Multiple-valve (MUV) procedures currently exhibit higher operative mortality than do single-valve procedures, but a paucity of scientific information exists to explain the observation. This topic was examined using The Society of Thoracic Surgeons Database.
METHODS: All patients in the The Society of Thoracic Surgeons data set undergoing valve surgery (except pulmonary valve and aortic root operations) from 1993 through 2007 were identified (N = 623,039). Baseline characteristics and postoperative outcomes were contrasted between all seven combinations of single-valve and MUV procedures involving aortic, mitral, and tricuspid valves. Seven independent logistic regression analyses were performed, based on the seven procedures, and multivariable risk factors for mortality were compared, with emphasis on single-valve versus MUV procedures.
RESULTS: Baseline characteristics for MUV procedures (n = 67,926) shared many similarities to those for single-valve procedures (n = 555,113), including age, ejection fraction, and comorbidities. Preoperative renal failure, New York Heart Association class III to IV, nonelective presentation, and reoperation were slightly more common in MUV subsets, and coronary bypass was less frequent. Operative mortality was almost double for MUV as compared with single-valve procedures (10.7% vs 5.7%, P = 0.0001). Categorical predictors with the largest odds ratios for mortality were emergency status, renal failure, and second reoperation. However, predictors for mortality were generally consistent in order and magnitude between the single-valve and MUV subgroups.
CONCLUSIONS: Despite similarities in preoperative profiles of the patients undergoing single-valve and MUV procedures, mortality for MUV surgery remains considerably higher. Determinants of operative mortality and morbidity differ little across the procedural groups, and these findings serve as a benchmark for future studies, as well as suggest a continued search for explanations of poorer MUV outcomes.

Entities:  

Mesh:

Year:  2014        PMID: 24402042     DOI: 10.1097/IMI.0000000000000028

Source DB:  PubMed          Journal:  Innovations (Phila)        ISSN: 1556-9845


  6 in total

1.  Outcomes of minimally invasive double valve surgery.

Authors:  Orlando Santana; Steve Xydas; Roy F Williams; Angelo LaPietra; Maurice Mawad; Frederick Hasty; Esteban Escolar; Christos G Mihos
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 2.  Minimally invasive valve surgery in high-risk patients.

Authors:  Orlando Santana; Steve Xydas; Roy F Williams; S Howard Wittels; Evin Yucel; Christos G Mihos
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

3.  Aortic valve replacement in patients with a left ventricular ejection fraction ≤35% performed via a minimally invasive right thoracotomy.

Authors:  Orlando Santana; Steve Xydas; Roy F Williams; Angelo La Pietra; Maurice Mawad; Vicente Behrens; Esteban Escolar; Christos G Mihos
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

4.  Outcomes of Guideline-Directed Concomitant Annuloplasty for Functional Tricuspid Regurgitation.

Authors:  Alexander A Brescia; Sarah T Ward; Tessa M F Watt; Liza M Rosenbloom; Megan Baker; Shazli Khan; Emilie Ziese; Matthew A Romano; Steven F Bolling
Journal:  Ann Thorac Surg       Date:  2019-08-31       Impact factor: 4.330

Review 5.  Pathophysiology and management of multivalvular disease.

Authors:  Philippe Unger; Marie-Annick Clavel; Brian R Lindman; Patrick Mathieu; Philippe Pibarot
Journal:  Nat Rev Cardiol       Date:  2016-04-28       Impact factor: 32.419

Review 6.  Multivalvular Disease: Percutaneous Management in 2019 and Beyond.

Authors:  Magdalena Erlebach; Rüdiger Lange
Journal:  Interv Cardiol       Date:  2019-11-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.